港安健康科普:
LYT-200是一种全人源单克隆抗体,旨在靶向强效致癌驱动因子和免疫抑制因...查看全文
Galectin(GALT)05-01 02:25
$Galectin(GALT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001133416-24-000042 Size: 5 KB 网页链接查看全文
Galectin(GALT)04-25 23:45
$Galectin(GALT)$ 5 Annual statement of changes in beneficial ownership of securities Accession Number: 0001493152-24-015879 Size: 7 KB 网页链接查看全文
港安健康04-15 18:47
转移性头颈癌的预后很差,中位生存期约为10个月。港安健康国际医疗介绍,近日,FDA已授予IgG4单克隆抗体LYT-200与PD-1免疫疗法联用治疗复发性或转移性头颈鳞状细胞癌(HNSCC)患者的快速通道指定。
港安健康科普:
LYT-200是一种全人源单克隆抗体,旨在靶向强效致癌驱动因子和免疫抑制因...查看全文
蹊之美股生物医药2021-07-14 20:40
作者:林出
微信公众号:蹊之美股生物医药 / CaesarBiotech
Gainers:
Allied Healthcare Products (NASDAQ:AHPI) +128%
SCWorx (NASDAQ:WORX) +19%
Dynatronics (NASDAQ:DYNT) +8%
Losers:
Meridian Bioscience (NASDAQ:VIVO) -22%
Simulations Plu...查看全文
牛唐2021-04-20 09:43
$Galectin治疗(GALT)$ 聘请世界著名神经外科医生、美国住房和城市发展部第17任部长Ben Carson博士担任特别顾问,股价大涨26%,一个人带来的市值提升。$快手-W(01024)$ $舜宇光学科技(02382)$查看全文
andrewmed2021-04-15 09:15
文章来源:“凯莱英药闻”微信公众号
4月13日,纳斯达克上市公司Galectin Therapeutics旗下半乳糖结合蛋白-3(Galectin-3)抑制剂——Belapectin (GR-MD-02)联合K药治疗晚期转移性黑色素瘤(MM)和头颈部鳞状细胞癌(HNSCC)的1期临床试验详细结果在Journal for ImmunoTherapy of Cancer(JITC)...查看全文
知行健2018-09-26 09:04
$Galectin Therapeutics Inc. (GALT)$ 我们是一家临床阶段生物制药公司,致力于药物的研究和开发,为纤维疾病、严重皮肤病和癌症创造新的治疗方法。我们的候选药物是基于我们的靶向性的高蛋白,这是生物和病理功能的关键中介。我们使用自然发生的,容易获得的植物产品作为制造过程中的起始材料,制...查看全文
WitnessBio2018-04-06 05:11
$Arrowhead制药(ARWR)$ $CymaBay Therapeutics Inc.(CBAY)$ $Galectin Therapeutics Inc.(GALT)$ 欧洲肝脏研究协会(EASL)年会将于四月11号到15号在巴黎召开。以下几个公司将会通报它们的最新进展,值得关注。
ARWR, ASMB, CBAY, GALT, GILD, ICPT, MDGL查看全文
$GALECTIN THERAPEUTICS INC(GALT)$ UPLOAD [Cover] - SEC-generated letter Filed: 2016-01-08 AccNo: 0000000000-16-060794 Size: 156 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ CORRESP [Cover] - Correspondence Filed: 2016-01-08 AccNo: 0001193125-16-424739 Size: 5 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-01-19 AccNo: 0000902664-16-004878 Size: 53 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-01-14 AccNo: 0001535610-16-000135 Size: 15 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ 8-K - Current report Filed: 2016-01-08 AccNo: 0001193125-16-424038 Size: 34 KBItem 1.02: Termination of a Material Definitive AgreementItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office...
$GALECTIN THERAPEUTICS INC(GALT)$ 8-K - Current report Filed: 2016-01-07 AccNo: 0001193125-16-422934 Size: 52 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ 8-K - Current report Filed: 2016-01-05 AccNo: 0001193125-16-420578 Size: 36 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2015-12-21 AccNo: 0001193125-15-409257 Size: 255 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ D - Notice of Exempt Offering of Securities Filed: 2015-12-21 AccNo: 0001133416-15-000001 Size: 15 KB 网页链接
$GALECTIN THERAPEUTICS INC(GALT)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2015-11-27 AccNo: 0001104659-15-081635 Size: 102 KB 网页链接